ivosidenib
FDA Approves Tibsovo for Myelodysplastic Syndromes
The FDA approved ivosidenib (Tibsovo, Servier Pharmaceuticals) for adult patients with relapsed or refractory ...
OCTOBER 26, 2023

New Treatment OK’d for Newly Diagnosed IDH1-Mutant AML
The FDA approved the combination of ivosidenib (Tibsovo, Servier) plus azacitidine for adults aged 75 years and ...
MAY 27, 2022

FDA Approves Tibsovo for Adjuvant Treatment of IDH1-Mutated UC
The FDA approved ivosidenib (Tibsovo, Servier) for adults with previously treated, locally advanced or metastatic ...
AUGUST 30, 2021

Load more